Tag Archive for: ionctura

iOnctura appoints Paul Sekhri as Chair of its Board of Directors

Paul Sekhri is a life science executive with more than 35 years of experience building and leading companies from early development through commercialization Appointment comes as iOnctura prepares for late-stage development of roginolisib, with its two randomized studies fully enrolled Strengthens iOnctura’s Board with extensive experience in company building, strategic transactions and financing Geneva, Switzerland […]

October in Overdrive: Inside Optimum’s 18th Annual Healthcare Investor Conference

Save the date: Optimum’s 19th Annual Healthcare Investor Conference — 7 October 2027. We look forward to seeing you there! 📸 Were you there? Find your photos and have your say! Find your photos, download your favourites and share them on social media, and don’t forget to tag Optimum so we can see them too. […]

iOnctura bolsters leadership team with new appointments

Steven Sciuto joins as Chief Financial Officer (CFO) bringing a wealth of experience in scaling finance functions as well as in private and public financings Michelle Tsai PharmD, with deep expertise in portfolio strategy and lifecycle planning, joins as Chief Operating Officer (COO) Geneva, Switzerland and Amsterdam, The Netherlands, 2 June 2025 – iOnctura, a […]

iOnctura commences randomized Phase I/II study in non-small cell lung cancer

First patient dosed in study investigating roginolisib + dostarlimab +/- docetaxel in patients with NSCLC who have progressed on prior immunotherapy/chemo Study will evaluate safety of the combination and explore whether targeting PI3Kδ with immunotherapy may rebalance the immune system to prevent or reverse resistance to current standard immunotherapy/chemo in NSCLC Geneva, Switzerland and Amsterdam, […]

iOnctura reaches new clinical milestones in uveal melanoma

Completed Phase I DIONE-01 study demonstrates clinical activity and long-term safety of roginolisib, a unique allosteric modulator of PI3Kδ Patients with uveal melanoma showed a doubling of overall survival compared to historical controls Site activation ongoing for randomized Phase II OCULE-01 study in uveal melanoma Geneva, Switzerland and Amsterdam, The Netherlands, 11 Dec 2024 – […]

© Optimum Strategic Communications.